Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Video interview with prof. Laura Q.M. Chow who discusses the results of the phase II ASCEND-7 study

2. Significant overall survival improvement by the addition of abemaciclib to fulvestrant in patients with
    advanced breast cancer

3. Maintenance niraparib significantly improves the progression-free survival of patients with newly
    diagnosed ovarian cancer

4. Frontline osimertinib improves the overall survival in patients with EGFR-mutation positive metastatic
    non-small cell lung cancer

5. Olaparib outperforms enzalutamide or abiraterone acetate in men with metastatic castration resistant
    prostate cancer with HRR alterations